Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nivolumab in Resected Merkel Cell Carcinoma
NCT02196961Phase 2Completed
- Start
- Jun 2014
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab in Merkel cell carcinoma (MCC). Started Jun 2014; status: completed.
02
Drugs
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT02196961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02196961.